Rocket Pharmaceuticals (RCKT) Highlights Updated Data from Phase 1/2 Gene Therapy Trial of RP-L102 – StreetInsider.com
|
Rocket Pharmaceuticals (RCKT) Highlights Updated Data from Phase 1/2 Gene Therapy Trial of RP-L102
StreetInsider.com Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) announced the presentation of updated data from the ongoing Phase 1/2 clinical trial of RP-L102, the Company's lead lentiviral vector (LVV)-based gene therapy, for Fanconi Anemia (FA). The data were … |
